Bio Gene Financials
| BGT Stock | 0.04 0 2.33% |
Operating Margin 2.2 K | Return On Equity (0.80) |
Bio | Select Account or Indicator |
Understanding current and past Bio Gene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bio Gene's financial statements are interrelated, with each one affecting the others. For example, an increase in Bio Gene's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Bio Gene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bio Gene Technology. Check Bio Gene's Beneish M Score to see the likelihood of Bio Gene's management manipulating its earnings.
Bio Gene Stock Summary
Bio Gene competes with Northern Star, Evolution Mining, Bluescope Steel, and Aneka Tambang. Bio Gene is entity of Australia. It is traded as Stock on AU exchange.| Foreign Associate | USA |
Specialization | Healthcare, Biotechnology |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU000000BGT8 |
| Business Address | 400 Collins Street, |
| Sector | Chemicals |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | www.bio-gene.com.au |
| Phone | 61 3 9068 1062 |
You should never invest in Bio Gene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bio Stock, because this is throwing your money away. Analyzing the key information contained in Bio Gene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bio Gene Key Financial Ratios
Bio Gene's financial ratios allow both analysts and investors to convert raw data from Bio Gene's financial statements into concise, actionable information that can be used to evaluate the performance of Bio Gene over time and compare it to other companies across industries.| Revenue | 18.32 K | |||
| Gross Profit | 222.1 K | |||
| EBITDA | (2.97 M) | |||
| Net Income | (2.41 M) | |||
| Total Asset | 3.16 M |
Bio Gene Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 6.6M | 5.0M | 7.3M | 3.8M | 3.2M | 5.0M | |
| Other Current Liab | 266.4K | 504.6K | 790.2K | 455.2K | 298.7K | 384.0K | |
| Net Tangible Assets | 4.6M | 5.7M | 3.9M | 6.0M | 6.9M | 3.6M | |
| Net Debt | (5.5M) | (3.9M) | (6.3M) | (3.0M) | (2.2M) | (2.3M) | |
| Retained Earnings | (9.5M) | (11.7M) | (14.5M) | (17.4M) | (19.6M) | (18.7M) | |
| Cash | 5.5M | 3.9M | 6.3M | 3.0M | 2.2M | 4.1M | |
| Total Liab | 567.3K | 754.6K | 1.0M | 613.9K | 368.4K | 601.7K | |
| Total Current Assets | 6.2M | 4.7M | 7.0M | 3.6M | 2.9M | 4.6M | |
| Intangible Assets | 351.0K | 314.0K | 277.1K | 240.1K | 203.2K | 252.5K | |
| Common Stock | 11.8M | 14.5M | 15.1M | 19.5M | 21.5M | 13.0M | |
| Net Receivables | 483.0K | 523.8K | 438.2K | 445.6K | 524.0K | 401.8K | |
| Accounts Payable | 134.0K | 88.1K | 219.0K | 118.7K | 47.2K | 44.9K | |
| Inventory | 102.6K | 132.9K | 148.8K | 70.2K | 80.7K | 84.8K | |
| Net Invested Capital | 6.0M | 4.2M | 6.3M | 3.2M | 2.8M | 4.4M | |
| Net Working Capital | 5.8M | 4.1M | 6.0M | 3.0M | 2.6M | 4.1M |
Bio Gene Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.0M | (1.6M) | 2.4M | (3.4M) | (781.0K) | (741.9K) | |
| Free Cash Flow | (1.6M) | (1.8M) | 36.7K | (3.3M) | (2.8M) | (2.6M) | |
| Depreciation | 58.4K | 54.2K | 43.5K | 45.3K | 38.4K | 39.4K | |
| Other Non Cash Items | 734.8K | 375.1K | 2.9M | 506.0K | 400.7K | 380.7K | |
| Net Income | (1.9M) | (2.4M) | (2.9M) | (3.1M) | (2.4M) | (2.5M) | |
| End Period Cash Flow | 5.5M | 3.9M | 6.3M | 3.0M | 2.2M | 3.3M | |
| Change To Netincome | 169.3K | 427.1K | 406.7K | 488.8K | 562.1K | 590.2K |
Bio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bio Gene's current stock value. Our valuation model uses many indicators to compare Bio Gene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Gene competition to find correlations between indicators driving Bio Gene's intrinsic value. More Info.Bio Gene Technology is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Gene's earnings, one of the primary drivers of an investment's value.Bio Gene Technology Systematic Risk
Bio Gene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bio Gene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Bio Gene Technology correlated with the market. If Beta is less than 0 Bio Gene generally moves in the opposite direction as compared to the market. If Bio Gene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bio Gene Technology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bio Gene is generally in the same direction as the market. If Beta > 1 Bio Gene moves generally in the same direction as, but more than the movement of the benchmark.
Bio Gene Technology Total Assets Over Time
Bio Gene Thematic Clasifications
Bio Gene Technology is part of Computers investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Computers | View |
Bio Gene December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bio Gene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bio Gene Technology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bio Gene Technology based on widely used predictive technical indicators. In general, we focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bio Gene's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.12 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 22.66 | |||
| Value At Risk | (7.27) | |||
| Potential Upside | 7.41 |
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.